AROMA: Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA

Sponsor
Danish Dementia Research Centre (Other)
Overall Status
Recruiting
CT.gov ID
NCT05740683
Collaborator
Danish Reference Center for Prion Diseases, Rigshospitalet (Other), Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet (Other)
100
2
118
50
0.4

Study Details

Study Description

Brief Summary

Test of early warning signs and RT-QuIC in patients with idiopathic olfactory dysfunction

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: RT-QuiC

Detailed Description

Background. The number of persons living with dementia is increasing in Denmark and worldwide because the population is generally growing older. Dementia with Lewy bodies (DLB) is the second most prevalent etiology among the neurodegenerative diseases that give rise to dementia.

DLB is characterized by many prodromal symptoms years before dementia is evident. Currently, little is known about the course of symptoms in the prodromal phase, and furthermore, the diagnosis of DLB can be clinically challenging, especially in the early stages. DLB is like Parkinson's disease (PD), characterized by the accumulation of alpha-synuclein, which misfolds and aggregates within neurons in so-called Lewy Bodies; this assumably drives the neurodegeneration. A novel technique for the measurement of misfolded alpha-synuclein is Real-Time Quaking-Induced Conversion (RT-QuIC), which may be able to support the diagnostic process as well as aid in identifying patients with prodromal DLB. This would enable earlier symptomatic relief and care and potentially promote the search for disease-modifying therapies, which is currently absent.

Objectives. The overarching objective of this project is to identify early clinical warning signs and biomarkers in prodromal DLB.

Method. Study 1: Exploratory cross-sectional case-control study of patients with olfactory dysfunction versus individuals without olfactory dysfunction assessing pathological alpha-synuclein by RT-QuIC and prodromal symptoms of DLB and Parkinson's Disease.

Study 2: Longitudinal follow-up in Danish registries on diagnosing PD and dementia.

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Alpha-synuclein Rt-quic and Neurologic Symptoms in Persons With idiOpathic anosMiA
Actual Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2032
Anticipated Study Completion Date :
Dec 1, 2032

Arms and Interventions

Arm Intervention/Treatment
People with idiopathic olfactory dysfunction

Diagnostic Test: RT-QuiC
RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.

People without olfactory dysfunction

Diagnostic Test: RT-QuiC
RT-QuIC measures the ability of aSyn to misfold other aSyn proteins and is an amplification technique.

Outcome Measures

Primary Outcome Measures

  1. Real-time quaking-induced conversion (RT-QuIC) positive for alpha-synuclein (aSyn) [24 months]

  2. Diagnosis of Parkinson's disease (PD) or dementia [8 years]

    A diagnosis of PD or dementia in national databases.

Secondary Outcome Measures

  1. Smell test [24 months]

    Sniffin Sticks identification test (SIT16)

  2. Smell test [24 months]

    Sniffin Sticks 48

  3. Motor function [24 months]

    Unified Parkinson's Rating Scale (UPDRS-III)

  4. Dysautonomia [24 months]

    Unified Parkinson's Rating Scale (UPDRS-I)

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years to 75 Years
Sexes Eligible for Study:
All
Inclusion criteria with patients iOD:
  • Age 55 -75 years of age

  • Slowly progressing and non-fluctuating iOD

  • Able to give informed consent and to cooperate as evaluated by the PI

Exclusion criteria with patients iOD:
  • Diagnosed with a neurodegenerative disease or major neurological/psychiatric condition.

  • Anosmia/hyposmia caused by sino-nasal disease (including chronic rhinitis and allergy), after trauma, infection, congenial, olfactory dysfunction due to surgery, or toxins/drugs affecting the olfactory function.

  • Olfactory dysfunction with response to systemic or local corticosteroids if tried

  • Severe nasal cavity abnormalities or infections.

  • Overt signs of dementia or PD

  • Current alcohol or drug abuse

  • Terminal illness

  • Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.

Inclusion criteria controls:
  • Age 55 -75 years of age

  • Able to give informed consent

  • Able to cooperate as evaluated by the PI

Exclusion criteria controls:
  • Olfactory dysfunction on clinical test

  • Overt signs of dementia or PD

  • Severe nasal cavity abnormalities or infections.

  • Current alcohol or drug abuse

  • Diagnosed with neurodegenerative disease or major neurological/psychiatric condition.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Danish Dementia Research Centre Copenhagen Denmark 2100
2 Oskar McWilliam Copenhagen Denmark 2100

Sponsors and Collaborators

  • Danish Dementia Research Centre
  • Danish Reference Center for Prion Diseases, Rigshospitalet
  • Department of Otorhinolaryngology, Head and Neck Surgery & Audiology, Rigshospitalet

Investigators

  • Principal Investigator: Kristian S Frederiksen, Danish Dementia Research Centre, Rigshospitalet, Capital Region
  • Principal Investigator: Oskar McWilliam, Danish Dementia Research Centre, Rigshospitalet, Capital Region
  • Principal Investigator: Steen G Hasselbalch, Danish Dementia Research Centre, Rigshospitalet, Capital Region
  • Principal Investigator: Gunhild Waldemar, Danish Dementia Research Centre, Rigshospitalet, Capital Region
  • Principal Investigator: Marie Brunn, Danish Dementia Research Centre, Rigshospitalet, Capital Region
  • Principal Investigator: Anja H Simmonsen, Danish Dementia Research Centre, Rigshospitalet, Capital Region

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Danish Dementia Research Centre
ClinicalTrials.gov Identifier:
NCT05740683
Other Study ID Numbers:
  • H-22053428
First Posted:
Feb 23, 2023
Last Update Posted:
Feb 23, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Danish Dementia Research Centre
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2023